Crystalline forms of pyrrolopyrimidine five-membered nitrogen heterocyclic compounds
By preparing the free alkali crystal form A and phosphate crystal form B of compound (I) through crystallization in different solvents, the problems of insufficient stability and solubility in the prior art are solved, a new crystal form suitable for clinical use is provided, bioavailability and efficacy are improved, and the preparation process is simplified.
Patent Information
- Application Number
- CN202111268081.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-10-30
- Filing Date
- 2021-10-29
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2041-10-29
AI Technical Summary
In the prior art, the solid compounds of formula (I) have high hygroscopicity, low stability and solubility, which cannot meet the needs of clinical pharmaceutical use.
The free base form A and phosphate form B of compound (I) are prepared by crystallization in different solvents. Specifically, the methods include crystallization in methanol, water, dimethyl sulfoxide/isopropyl acetate, dimethyl sulfoxide/toluene, or ethanol/water to prepare new crystal forms with characteristic peaks.
It provides a new crystal form with good stability and high solubility, meeting the requirements of bioavailability and efficacy, simplifying the preparation process, reducing storage and quality control costs, and is suitable for the treatment of autoimmune diseases such as rheumatoid arthritis.
Smart Images

Figure CN114437079B_ABST
Abstract
Description
[0001] This application claims the priority of a prior application with application number 202011199567.8, filed with the State Intellectual Property Office on October 30, 2020, and invention name “Crystalline Form of Five-membered Nitrogen Heterocyclic Compound of Pyrrolidine”, which is incorporated into this application by reference in its entirety. Technical Field
[0002] The present invention belongs to the technical field of drug crystal forms, and in particular relates to a new crystal form of a pyrrolopyrimidine five-membered nitrogen heterocyclic compound, and a preparation method and application thereof. Background Art
[0003] JAK (Janus kinase) kinase is a family of intracellular non-receptor tyrosine kinases that mediate the signals produced by cytokines and transmit them through the JAK-STAT signaling pathway. There are currently four known JAK family members: JAK kinase 1 (JAK1), JAK kinase 2 (JAK2), JAK kinase 3 (JAK3) and Tyrosine Kinase 2 (TYK2). JAK-dependent cytokines are involved in the pathogenesis of a variety of inflammatory and autoimmune diseases, and JAK inhibitors may be widely used to treat various inflammatory diseases.
[0004] Patent CN201710055590.1 discloses a compound represented by formula (I), which is a novel JAK kinase inhibitor with high selectivity for JAK2. When used as a therapeutic agent for JAK kinase-related diseases such as rheumatoid arthritis, polycythemia vera, psoriasis, essential thrombocythemia, and myelofibrosis, it can reduce side effects and improve safety.
[0005]
[0006] The solid compound prepared according to patent CN201710055590.1 has high hygroscopicity, low stability, solubility and bioavailability, and cannot meet clinical medicinal needs.
[0007] Different crystal forms of solid chemical drugs may result in different solubility and stability, thereby affecting the absorption and bioavailability of the drug and leading to differences in clinical efficacy. However, there are currently no reports on the crystal forms of the compound of formula (I). Therefore, it is necessary to conduct a comprehensive and systematic polymorph screening of the compound of formula (I) to select the most suitable crystal form for development. Summary of the invention
[0008] The object of the present invention is to provide a new crystal form of the compound of formula (I), a preparation method of the new crystal form and use thereof;
[0009]
[0010] The purpose of the present invention can be achieved by the following technical solutions:
[0011] The present invention first provides a crystalline form A of a compound represented by formula (I), wherein the X-ray powder diffraction pattern of the crystalline form A expressed in 2θ angles has the following characteristic peaks: 5.6±0.2°, 16.9±0.2°, 18.4±0.2°, 18.6±0.2° and 28.3±0.2°.
[0012] Preferably, the crystalline form A provided by the present invention also has characteristic peaks at 2θ of 11.2±0.2°, 12.0±0.2°, 12.9±0.2°, 13.4±0.2°, 14.8±0.2°, 17.6±0.2°, 19.3±0.2°, 20.5±0.2°, 21.3±0.2°, 22.5±0.2°, 23.0±0.2°, 24.8±0.2°, 25.4±0.2°, 27.9±0.2°, 30.0±0.2°, 30.7±0.2°, 33.4±0.2°, and 34.9±0.2°.
[0013] More preferably, the crystal form A provided by the present invention has an X-ray powder diffraction pattern substantially similar to Figure 1 Consistent.
[0014] The crystal form A provided by the present invention has TGA and DSC results as shown in Figure 2 As shown, the sample loses 1.9% of its weight when heated to 150°C, and an endothermic peak begins to appear around 234.1°C. It can be seen that Form A is an anhydrous crystal form.
[0015] The present invention also relates to a method for preparing the crystal form A: the phosphate of the compound of formula (I) is crystallized in methanol, water, dimethyl sulfoxide / isopropyl acetate, dimethyl sulfoxide / toluene or ethanol / water.
[0016] When the inventors of the present application conducted a study on the crystal form of the compound of formula (I), they found that the solubility of the compound of formula (I) was extremely low, and most solvents could not dissolve it, so it was impossible to study its crystal form. When the inventors of the present application conducted a study on the crystal form of its phosphate, they unexpectedly found that the phosphate crystal form would be converted into the free base crystal form of the compound of formula (I) under certain conditions. For example, it was observed that the phosphate crystal form can be disproportionated into the free base crystal form A in various systems such as methanol, ethanol, isopropanol, N,N-dimethylformamide, and water. Through further research, it was found that the free base crystal form of the compound of formula (I) can be obtained by crystallizing the phosphate of the compound of formula (I) in some solvents, such as methanol, water, dimethyl sulfoxide / isopropyl acetate, dimethyl sulfoxide / toluene or ethanol / water, and it was named crystal form A.
[0017] When ethanol / water is used for crystallization, when the ratio of ethanol to water is less than 6:1, the free base crystal form A of the compound of formula (I) is obtained.
[0018] Preferably, methanol, water, dimethyl sulfoxide / isopropyl acetate or dimethyl sulfoxide / toluene is used as a solvent for crystallization to prepare the free base form A of the compound of formula (I).
[0019] Another object of the present invention is to provide a phosphate crystal form B of the compound of formula (I), wherein the X-ray powder diffraction pattern of the crystal form B expressed in 2θ angles has the following characteristic peaks: 15.19±0.2°, 18.56±0.2°, 22.89±0.2°.
[0020] Preferably, the crystalline form B provided by the present invention also has characteristic peaks at 2θ of 7.63±0.2°, 10.57±0.2°, 13.59±0.2°, 14.41±0.2°, 16.22±0.2°, 16.73±0.2°, 18.21±0.2°, 19.05±0.2°, 19.47±0.2°, 20.51±0.2°, 21.16±0.2°, and 21.94±0.2°.
[0021] More preferably, the crystal form B provided by the present invention has an X-ray powder diffraction pattern substantially similar to Figure 3 Consistent.
[0022] The crystal form B provided by the present invention has TGA and DSC results as shown in Figure 4 As shown, the sample loses 2.0% of its weight before 150°C, and an endothermic peak begins to appear around 216.3°C. It can be seen that Form B is an anhydrous crystal form.
[0023] The present invention provides a method for preparing the crystal form B: the crystal form B is prepared by reacting a compound of formula (I) and phosphoric acid in an ethanol / acetonitrile solvent.
[0024] Among them, when the volume ratio of ethanol to acetonitrile is 1:3, the phosphate crystal form B of the compound of formula (I) can be obtained satisfactorily. According to IC detection, the phosphate crystal form B of the compound of formula (I) obtained is 4 3- The ion content is 19.3% (theoretical value 19.1%), so one molecule of free base in form B is combined with one molecule of phosphoric acid.
[0025] When the inventors of the present application used other organic solvents, such as ethanol, acetone, ethyl acetate, methyl tert-butyl ether, 2-methyltetrahydrofuran, etc. as reaction solvents, the phosphate ion content in the obtained solid was somewhat different from the theoretical value. When a mixed solvent of ethanol / acetonitrile with a volume ratio of 3:1 was used, no phosphate compound could be obtained.
[0026] Preferably, when preparing Form B, the molar ratio of phosphoric acid to the compound of formula (I) is above 1.5.
[0027] The inventors of the present application have studied the disproportionation phenomenon of Form B. In an ethanol solution, Form B is directly stirred for 4 days, and part of it is disproportionated into free base Form A. However, when the free base solid of Formula (I) and 1.5 equivalents or more of phosphoric acid are stirred in ethanol for 3 days, only phosphate Form B is generated. Therefore, when preparing phosphate Form B, more than 1.5 equivalents of phosphoric acid need to be added.
[0028] The present invention also provides a crystalline form C of the compound of formula (I). Its X-ray powder diffraction pattern is substantially the same as Figure 5 Form C can be prepared by crystallization of Form B in a mixed solvent of DMF and DCM, but after being left at room temperature overnight, it transforms into a mixed form of free base Form A and phosphate Form B.
[0029] Another object of the present invention is to provide a pharmaceutical composition comprising an effective therapeutic amount of Form A or Form B and a pharmaceutically acceptable carrier, diluent or excipient.
[0030] The free base new crystal form A, the phosphate new crystal form B or a mixture of the free base new crystal form A and the phosphate new crystal form B of the compound of formula (I) provided by the present invention can be used for the preparation of drugs for treating autoimmune diseases, especially for the use of drug preparations for treating rheumatoid arthritis.
[0031] In summary, there is no patent or literature reporting the crystal form of the compound of formula (I). The solubility of the compound of formula (I) is very low, making it difficult to study the crystal form. The inventors of the present invention have overcome this difficulty and found two new crystal forms suitable for development.
[0032] The crystal form provided by the present invention has good stability and remarkable process purification effect, and can well avoid crystal transformation during drug storage and development, thereby avoiding changes in bioavailability and efficacy.
[0033] The crystal forms A and B provided by the present invention have no hygroscopicity or low hygroscopicity, meet the requirements of bioavailability and efficacy, do not require special drying conditions in the preparation process, simplify the preparation process and post-treatment process of the drug, are not easily affected by humidity, have no stringent requirements on storage conditions, are convenient for long-term storage, greatly reduce the cost of material storage and quality control, and have strong economic value.
[0034] In summary, the crystal forms A and B provided by the present invention have significant improvements over the prior art, especially compared with the solid compound prepared in Example 1 of patent CN201710055590.1, they have lower hygroscopicity, higher stability, solubility and bioavailability, which provides support for future formulation research, thereby meeting different clinical medication needs. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] Figure 1 is an X-ray powder diffraction (XRD) pattern of Form A of the present invention;
[0036] Figure 2 It is the thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) diagram of the crystal form A of the present invention;
[0037] Figure 3 is an X-ray powder diffraction (XRD) pattern of the phosphate crystal form B of the present invention;
[0038] Figure 4 It is the thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) diagram of the phosphate crystal form B of the present invention;
[0039] Figure 5 is an X-ray powder diffraction (XRD) pattern of Form C of the present invention;
[0040] Figure 6 is a dynamic moisture sorption (DVS) graph of the free base crystalline form A of the present invention;
[0041] Figure 7 is an XRPD overlay of the free base form A of the present invention before and after the dynamic moisture sorption (DVS) test;
[0042] Figure 8 is a dynamic moisture adsorption (DVS) diagram of the phosphate crystal form B of the present invention;
[0043] Fig. 9 It is an XRPD overlay of the phosphate crystal form B of the present invention before and after the dynamic moisture sorption (DVS) test. DETAILED DESCRIPTION
[0044] In order to better understand the content of the present invention, the technical solution of the present invention is further described below in conjunction with specific embodiments, but the specific implementation methods do not mean any limitation to the present invention.
[0045] Testing instruments and methods:
[0046] The instrument used for X-ray powder diffraction (XRD) is a Bruker D8 Advance Diffractometer, equipped with a θ-2θ goniometer, a Mo monochromator, and a Lynxeye detector. The acquisition software is Diffrac Plus XRDCommander, and the analysis software is MDI Jade 5.0. The instrument is calibrated with the standard material (usually corundum) that comes with the instrument before use. The detection conditions are: 2θ scanning angle range 3 to 40°, step length 0.013°, continuous scanning for 7 minutes. Detection process: Ka X-rays with a copper target wavelength of 1.54nm are used. Under the operating conditions of 45kV and 40mA, the samples are tested at room temperature, and the samples to be tested are placed on organic glass slides. Unless otherwise specified, the samples are not ground before testing.
[0047] Thermogravimetric analysis (TGA): instrument model: TA / TGA Q500, purge gas: nitrogen 40 ml / min, heating rate: 10°C / min, temperature range: 5°C to 350°C.
[0048] Differential scanning calorimeter (DSC): Instrument model: TA / DSC Q200, purge gas: nitrogen 40 ml / min, heating rate: 10°C / min, temperature range: 20°C to 250°C.
[0049] Dynamic moisture adsorption instrument (DVS): purge gas: nitrogen 200 ml / min, heating rate: 10°C / min, dm / dt: 0.002% / min, RH range: 0%RH-95%RH-0%RH, RH gradient: 5%.
[0050] The solid used in the example was prepared with reference to Example 1 of patent CN201710055590.1.
[0051] Example 1
[0052] A solution of free base solid (53 g, 0.1328 mol) dissolved in acetonitrile (2.4 L) and ethanol (800 mL) was added to the reaction flask, and phosphoric acid (20 g, 0.2 mol) was added, and stirred at 80°C overnight. The reaction system was cooled to room temperature, and solid precipitated. After filtration, phosphate crystal form B solid (50.3 g, yield: 76%, PO 4 3- Content: 19.3%).
[0053] MS(m / s):400[M+H] + ;
[0054] 1H-NMR (400MHz, DMSO-d6): δ1.17(t,J=7.4Hz,3H),2.14(m,J=8.0Hz,2H),2.83(d,J=10Hz,2H),2.96(t,J=10.6Hz,2H),3.05(m,J=7.3Hz,2 H), 3.29 (s, 2H), 3.56 (m, J = 4.2Hz, 2H), 7.10 (m, J = 1.7Hz, 1H), 7.63 (t, J = 2.0Hz, 1H), 8.45 (s, 1H), 8.71 (s, 1H), 8.82 (s, 1H), 12.15 (s, 1H).
[0055] Using a similar method, when acetonitrile was used as solvent, the PO 4 3- The content is 23.1%. When ethanol or isopropanol is used as solvent, the PO content in the obtained solid is 4 3- The content is about 22.1%.
[0056] Example 2
[0057] Weigh about 15 mg of phosphate crystal form B into a 20 ml vial, add dimethyl sulfoxide to dissolve until clear, add isopropanol dropwise to the clear solution, and stir while adding until solid precipitates. Collect the solid and perform XRPD test to obtain free base crystal form A. XRPD spectrum is shown in Figure 1 .
[0058] The same experimental method was used to obtain phosphate crystal form B using dimethyl sulfoxide / methyl isobutyl ketone, dimethyl sulfoxide / ethyl acetate, N / N-dimethylformamide / toluene, N / N-dimethylformamide / isopropyl acetate, N / N-dimethylformamide / 1,4-dioxane, N / N-dimethylformamide / methyl tert-butyl ether, ethanol / dichloromethane (1:2) / toluene, ethanol / dichloromethane (1:2) / n-heptane as crystallization solvents. The XRPD spectrum is shown in Figure 3 .
[0059] Example 3
[0060] Weigh about 10 mg of phosphate crystal form B into a 3 ml vial, add about 2.0-2.4 mL of methanol to prepare a clear solution, or filter with a nylon filter membrane (0.45 μm) to obtain a clear solution, place it at room temperature and seal it with a sealing film, pierce 2 to 4 small holes and let it evaporate naturally, collect the resulting solid and perform XRPD testing to obtain free base crystal form A.
[0061] By adopting the same experimental method, phosphate crystal form B was obtained using ethanol / dichloromethane (v / v=1:2) and ethanol / chloroform (v / v=1:3) as crystallization solvents.
[0062] Example 4
[0063] About 15 mg of each portion of phosphate crystal form B was weighed and dissolved in a certain amount of solvent 1, and the filtrate was filtered and placed in a 3 ml vial. Another 20 ml vial was taken and about 3 ml of solvent 2 was added thereto. The 3 ml vial was placed open in a 20 ml vial, sealed and left to stand at room temperature. When solid precipitation was observed, the solid was taken out for XRPD testing. The test results are shown in Table 1.
[0064] Table 1
[0065]
[0066] After being placed at room temperature overnight, Form C transforms into a mixture of free base Form A and phosphate Form B. The XRPD comparison spectrum is shown in Figure 5 .
[0067] Example 5
[0068] Weigh about 20 mg of phosphate crystal form B into a 3 ml vial, add 1.0 mL of a mixed solvent of dimethyl sulfoxide / toluene (v / v=1:5), stir at 50°C for 1 hour, filter the clear solution (polytetrafluoroethylene filter membrane, 0.45 μm), cool the filtrate from 50°C to 5°C at a rate of 0.1°C / min and keep it at 5°C. If the sample is clear, transfer it to room temperature for volatilization. Collect the precipitated solid and perform XRPD analysis to obtain free base crystal form A.
[0069] Using the same experimental method, when ethanol / chloroform (v / v=1:3) was used as the crystallization solvent, phosphate crystal form B was obtained. When N,N-dimethylformamide / methyl isobutyl ketone (v / v=1:5) or methanol / water (v / v=3:1) was used as the crystallization solvent, the system was clear and no solid was precipitated.
[0070] Example 6
[0071] About 15 mg of each phosphate crystal form B was weighed into a 1.5 ml glass vial, and 0.5 ml of the solvent listed in Table 2 was added respectively. The resulting suspension was stirred at room temperature for about 4 days, and then the solid was collected by centrifugation and subjected to XRPD testing. The test results are shown in Table 2.
[0072] Table 2
[0073]
[0074]
[0075] Example 7
[0076] About 20 mg of each phosphate crystal form B sample was weighed into an HPLC glass vial, and 0.5 mL of methanol was added. The resulting suspension was stirred at 50° C. for about 4 days, and then the solid was collected by centrifugation and subjected to XRPD testing to obtain the free base crystal form A.
[0077] By the same experimental method, when acetone, ethyl acetate, chloroform, tetrahydrofuran, 2-methyltetrahydrofuran or acetonitrile is used as the crystallization solvent, the phosphate crystal form B is obtained. When ethanol is used as the solvent, a mixed crystal of the free base crystal form A and the phosphate crystal form B is obtained.
[0078] Example 8
[0079] In order to evaluate the disproportionation risk of phosphate crystal form B in EtOH, the stability of phosphate crystal form B at different acid-base molar ratios was investigated at room temperature. The results are shown in Table 3 below.
[0080] Table 3
[0081]
[0082]
[0083] Example 9
[0084] To evaluate the stability of free base form A and phosphate form B under different humidity conditions, the samples were pre-dried at 0% RH to remove possible adsorbed solvents or water, and DVS tests were performed at a constant temperature of 25°C.
[0085] When the humidity reaches 80%, the moisture adsorption of free base crystal form A is 0.015%, indicating that the free base crystal form A has almost no hygroscopicity, and the crystal form remains unchanged before and after the DVS test. Figure 6 and attached Figure 7 The water adsorption of phosphate crystal form B is 1.17%, indicating that phosphate crystal form B has slight hygroscopicity. The XRPD results show that the crystal form of the sample remains unchanged before and after the DVS test, as shown in the attached Figure 8 and attached Fig. 9 shown.
[0086] Example 10
[0087] The solid state stability of free base form A and phosphate form B under different conditions was investigated. The conditions and results are shown in Table 4 below.
[0088] Table 4
[0089] The results show that the crystal form and purity of the free base crystal form A and the phosphate crystal form B samples did not change significantly, which shows that the free base crystal form A and the phosphate crystal form B have good physical and chemical stability.
[0090] Embodiment 11
[0091] Bioavailability test of free base form A
[0092] Experimental animals: 6 male CD-1 mice.
[0093] Dosage regimen: The intravenous dose is 1.0 mg / kg, the dosing volume is 1 mL / kg; the oral dose is 5 mg / kg.
[0094] Preparation of intravenous injection: Weigh an appropriate amount of OB756 and dissolve it with 5% DMAC, 5% solutol and 90% saline to a concentration of 0.2 mg / mL.
[0095] Oral preparation: Weigh an appropriate amount of OB756 and prepare it into a uniform suspension with 0.5% MC and 0.4% Tween80 at a concentration of 0.5 mg / mL.
[0096] Mouse blood samples were measured by LC-MS, and the results showed that the average bioavailability (F) of the free base Form A in CD-1 mice was 28.8%.
Claims
1. A crystalline form A of a compound represented by formula (I), characterized in that: The X-ray powder diffraction pattern of the crystalline form A expressed in 2θ angle has the following characteristic peaks: 5.6±0.2°, 16.9±0.2°, 18.4±0.2°, 18.6±0.2° and 28.3±0.2°; 2. The crystalline form A according to claim 1, characterized in that: The X-ray powder diffraction pattern of the crystalline form A also has characteristic peaks at 2θ of 11.2±0.2°, 12.0±0.2°, 12.9±0.2°, 13.4±0.2°, 14.8±0.2°, 17.6±0.2°, 19.3±0.2°, 20.5±0.2°, 21.3±0.2°, 22.5±0.2°, 23.0±0.2°, 24.8±0.2°, 25.4±0.2°, 27.9±0.2°, 30.0±0.2°, 30.7±0.2°, 33.4±0.2°, and 34.9±0.2°.
3. The crystalline form A according to claim 1, characterized in that: Its X-ray powder diffraction pattern is basically consistent with that in FIG1 .
4. A method for preparing the crystalline form A according to any one of claims 1 to 3, characterized in that: The phosphate salt of the compound of formula (I) is prepared by crystallization in methanol, water, dimethyl sulfoxide / toluene or ethanol / water.
5. The method for preparing Form A according to claim 4, characterized in that: The phosphate salt of the compound of formula (I) is prepared by crystallization in methanol, water, or dimethyl sulfoxide / toluene.
6. A pharmaceutical composition, comprising an effective therapeutic amount of the crystalline form A according to any one of claims 1 to 3 and a pharmaceutically acceptable carrier, diluent or excipient.
